Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2/3 Study of Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease

NCT04723537 is registered in ClinicalTrials.gov with RedHill Biopharma Limited as lead sponsor.

NCT NCT04723537
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04723537 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2/3 Study of Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease
Lead sponsor
RedHill Biopharma Limited
Phase
Phase 2/3
Overall status
Terminated
Start date
February 16, 2021
Completion date
December 28, 2021
Enrollment
61 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

covid19